SMI DRUG DISCOVERY LIMITED - Profile & Financials

Accounts Submitted 15 Apr 2025

Confirmation Statement Submitted

Net assets £1.13M £317.17K 2024 year on year

Total assets £0.00 £923.22K 2024 year on year

Total Liabilities £86.61K £22.10K 2024 year on year

Charges None No charges registered

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Contact

Update Details

Registered Address

23 Longmeadow Lode Cambridge CB25 9HA United Kingdom

Office (Newmarket)

SMi Drug Discovery, Newmarket CB8 0AT

Website

smidrugdiscovery.co.uk

Credit Report

Discover SMI DRUG DISCOVERY LIMITED's Credit Score, limit, and payment likelihood.

Mutual Companies

See All Mutual Companies

Financials

Period 1 Jan → 31 Dec 2024

Type Total Exemption Full

Next accounts 31 December 2025

Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2018–2024)

Cash in Bank

£668.80k

Increased by £184.71k (+38%)

Net Assets

£1.13M

Increased by £317.17k (+39%)

Total Liabilities

£86.61k

Decreased by £22.10k (-20%)

Turnover

N/A

Employees

Increased by 1 (+8%)

Debt Ratio

N/A

Decreased by 12 (-100%)

Financial History

Revenue, profit, EBITDA and key financial figures

	2024 Dec Year End	2023 Dec Year End
P&L
Revenue	£142.3M	£128.7M
Gross Profit	£48.2M	£43.1M
Operating Profit	£22.4M	£19.8M
Net Profit	£18.1M	£15.9M
EBITDA	£31.5M	£28.2M
Assets
Cash	£24.7M	£21.3M
Total Assets	£89.4M	£82.1M
Liabilities
Total Liabilities	£45.2M	£41.8M
Key Metrics
Employees	1,247	1,156

Latest Revenue

£142.3M

Latest EBITDA

£31.5M

Cash Position

£24.7M

Funding

Fundraising & Grants

£724k awarded

Show:

Investors (0)

No investor information available

Share Capital

Share allotments and capital structure

24 Allotments 8,643,623 Shares £14623.77m Total

Date From	Share Class	Shares Allotted	Amount Raised	Price/Share
12 Nov 2025	A1 SHARES	95,342	£303k	£3.18
26 Sept 2025	A1 SHARES	318,599	£1.01m	£3.18
9 Sept 2025	A1 SHARES	37,736	£120k	£3.18
8 Sept 2025	A1 SHARES	102,204	£325k	£3.18
27 Jun 2025	A1 SHARES	15,723	£50k	£3.18

Officers

5 active

Show resigned officers

						Status
Andrew James Thompson	Director	British	United Kingdom	52	29 Jan 2018	Active
James John Clark	Director	British	England	53	3 Jul 2019	Active
John Hirst	Director	British	England	73	21 Sept 2021	Active
Ronald Andrews	Director	American	United States	66	31 Oct 2025	Active
Stephen Little	Director	British	England	69	21 Sept 2021	Active

Shareholders

Shareholders (13)


Steve Reeder	3.2%	285,000	A2 Shares	14 Jan 2025
Stephen Little	1.1%	100,000	B Shares	14 Jan 2025
Stefan Hamill	0.6%	50,000	B Shares	14 Jan 2025

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased

Norcliffe Nominees Limited

United Kingdom

Active

Notified 1 Feb 2022

Nature of Control

Ownership Of Shares 25 To 50 Percent
Voting Rights 25 To 50 Percent

Andrew James Thompson

Ceased 3 Apr 2025

Ceased

See All Controllers

Group Structure

NORCLIFFE NOMINEES LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent

WOODSIDE SECRETARIES LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent

WOODSIDE GROUP HOLDINGS LIMITED united kingdom

SMI DRUG DISCOVERY LIMITED Current Company

Charges

No charges registered

Documents

Company Filings

Date	Category	Description	Document
2 Dec 2025	Incorporation	Memorandum Articles	View(32 pages)
13 Nov 2025	Capital	Allotment of shares (GBP 9,461.623) on 2025-11-12	View(4 pages)
3 Nov 2025	Officers	Appointment of Mr Ronald Andrews as director on 2025-10-31	View(2 pages)
29 Sept 2025	Capital	Allotment of shares (GBP 9,366.281) on 2025-09-26	View(4 pages)
24 Sept 2025	Persons With Significant Control	Cessation of Andrew James Thompson as a person with significant control on 2025-04-03	View(1 page)